527 related articles for article (PubMed ID: 27098822)
1. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.
Dickstein Y; Leibovici L; Yahav D; Eliakim-Raz N; Daikos GL; Skiada A; Antoniadou A; Carmeli Y; Nutman A; Levi I; Adler A; Durante-Mangoni E; Andini R; Cavezza G; Mouton JW; Wijma RA; Theuretzbacher U; Friberg LE; Kristoffersson AN; Zusman O; Koppel F; Dishon Benattar Y; Altunin S; Paul M;
BMJ Open; 2016 Apr; 6(4):e009956. PubMed ID: 27098822
[TBL] [Abstract][Full Text] [Related]
2. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Paul M; Daikos GL; Durante-Mangoni E; Yahav D; Carmeli Y; Benattar YD; Skiada A; Andini R; Eliakim-Raz N; Nutman A; Zusman O; Antoniadou A; Pafundi PC; Adler A; Dickstein Y; Pavleas I; Zampino R; Daitch V; Bitterman R; Zayyad H; Koppel F; Levi I; Babich T; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L
Lancet Infect Dis; 2018 Apr; 18(4):391-400. PubMed ID: 29456043
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial.
Rosso-Fernández C; Garnacho-Montero J; Antonelli M; Dimopoulos G; Cisneros JM;
Trials; 2015 Mar; 16():102. PubMed ID: 25872790
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
5. Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity.
Daitch V; Paul M; Daikos GL; Durante-Mangoni E; Yahav D; Carmeli Y; Benattar YD; Skiada A; Andini R; Eliakim-Raz N; Nutman A; Zusman O; Antoniadou A; Cavezza G; Adler A; Dickstein Y; Pavleas I; Zampino R; Bitterman R; Zayyad H; Koppel F; Zak-Doron Y; Levi I; Babich T; Turjeman A; Ben-Zvi H; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L
BMC Infect Dis; 2021 Mar; 21(1):309. PubMed ID: 33789574
[TBL] [Abstract][Full Text] [Related]
6. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.
Harris PN; Peleg AY; Iredell J; Ingram PR; Miyakis S; Stewardson AJ; Rogers BA; McBryde ES; Roberts JA; Lipman J; Athan E; Paul SK; Baker P; Harris-Brown T; Paterson DL
Trials; 2015 Jan; 16():24. PubMed ID: 25623485
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
Kasiakou SK; Michalopoulos A; Soteriades ES; Samonis G; Sermaides GJ; Falagas ME
Antimicrob Agents Chemother; 2005 Aug; 49(8):3136-46. PubMed ID: 16048915
[TBL] [Abstract][Full Text] [Related]
8. Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial.
Cisneros JM; Rosso-Fernández CM; Roca-Oporto C; De Pascale G; Jiménez-Jorge S; Fernández-Hinojosa E; Matthaiou DK; Ramírez P; Díaz-Miguel RO; Estella A; Antonelli M; Dimopoulos G; Garnacho-Montero J;
Crit Care; 2019 Nov; 23(1):383. PubMed ID: 31779711
[TBL] [Abstract][Full Text] [Related]
9. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.
Rosso-Fernández C; Sojo-Dorado J; Barriga A; Lavín-Alconero L; Palacios Z; López-Hernández I; Merino V; Camean M; Pascual A; Rodríguez-Baño J;
BMJ Open; 2015 Mar; 5(3):e007363. PubMed ID: 25829373
[TBL] [Abstract][Full Text] [Related]
10. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes.
Nutman A; Lellouche J; Temkin E; Daikos G; Skiada A; Durante-Mangoni E; Dishon-Benattar Y; Bitterman R; Yahav D; Daitch V; Bernardo M; Iossa D; Zusman O; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L; Paul M; Carmeli Y;
Clin Microbiol Infect; 2020 Sep; 26(9):1185-1191. PubMed ID: 32251844
[TBL] [Abstract][Full Text] [Related]
11. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
[TBL] [Abstract][Full Text] [Related]
12. Colistin combination therapy improves microbiologic cure in critically ill patients with multi-drug resistant gram-negative pneumonia.
Parchem NL; Bauer KA; Cook CH; Mangino JE; Jones CD; Porter K; Murphy CV
Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1433-9. PubMed ID: 27230510
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
Kaye KS; Shorr AF; Wunderink RG; Du B; Poirier GE; Rana K; Miller A; Lewis D; O'Donnell J; Chen L; Reinhart H; Srinivasan S; Isaacs R; Altarac D
Lancet Infect Dis; 2023 Sep; 23(9):1072-1084. PubMed ID: 37182534
[TBL] [Abstract][Full Text] [Related]
14. Influence of Colistin Dose on Global Cure in Patients with Bacteremia Due to Carbapenem-Resistant Gram-Negative Bacilli.
Gibson GA; Bauer SR; Neuner EA; Bass SN; Lam SW
Antimicrob Agents Chemother; 2016 Jan; 60(1):431-6. PubMed ID: 26525802
[TBL] [Abstract][Full Text] [Related]
15. Treatment and Outcome of Carbapenem-Resistant Gram-Negative Bacilli Blood-Stream Infections in a Tertiary Care Hospital.
Shah PG; Shah SR
J Assoc Physicians India; 2015 Jul; 63(7):14-8. PubMed ID: 26731822
[TBL] [Abstract][Full Text] [Related]
16. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance.
Werarak P; Kiratisin P; Thamlikitkul V
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S126-38. PubMed ID: 20364567
[TBL] [Abstract][Full Text] [Related]
17. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia.
Yilmaz GR; Guven T; Guner R; Kocak Tufan Z; Izdes S; Tasyaran MA; Acikgoz ZC
J Infect Dev Ctries; 2015 May; 9(5):476-85. PubMed ID: 25989167
[TBL] [Abstract][Full Text] [Related]
18. The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study.
Zak-Doron Y; Dishon Benattar Y; Pfeffer I; Daikos GL; Skiada A; Antoniadou A; Durante-Mangoni E; Andini R; Cavezza G; Leibovici L; Yahav D; Eliakim-Raz N; Carmeli Y; Nutman A; Paul M;
Clin Infect Dis; 2018 Nov; 67(12):1815-1823. PubMed ID: 29718143
[TBL] [Abstract][Full Text] [Related]
19. Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: a systematic review and meta-analysis.
Gu WJ; Wang F; Tang L; Bakker J; Liu JC
Int J Antimicrob Agents; 2014 Dec; 44(6):477-85. PubMed ID: 25199968
[TBL] [Abstract][Full Text] [Related]
20. Clinical and microbiological efficacy and toxicity of colistin in patients infected with multidrug-resistant gram-negative pathogens.
Yılmaz GR; Baştuğ AT; But A; Yıldız S; Yetkin MA; Kanyılmaz D; Akıncı E; Bodur H
J Infect Chemother; 2013 Feb; 19(1):57-62. PubMed ID: 22806446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
